ArticleClinical pharmacology in drug development2026
A Phase 1, Open-Label, Single-Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor.
Wei Zhu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.